LXP5101

This product is a new drug with new indications. It was originally a blood pressure-lowering drug. It has obtained 5 cancer inhibition patents in Taiwan and Australia. It has been seen in recent international journals that this drug is used in combination with radiotherapy. Blocking CD47/SIRPα and The combination of TIGIT/PVR can increase the number and activation of CD8+ T cells in local tumor sites, draining lymph nodes and spleen to exert the effect of inhibiting colorectal cancer.